ArticleCureus2026
A Cross-Sectional Study of CD163 Expression and CD8-Positive Tumor-Infiltrating Lymphocytes in Glial Tumors at a Tertiary Care Center.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective Glial tumors are increasingly recognized as immunologically active neoplasms in which macrophage-rich and lymphocyte-poor microenvironments may influence aggressiveness. Cluster of differentiation 163 (CD163) highlights tumor-associated macrophages, whereas CD8 marks cytotoxic tumor-infiltrating lymphocytes (TILs). This study aimed to evaluate CD163 expression and CD8-positive TILs in glial tumors and examine their association with tumor grade. Methods This cross-sectional study included 50 histopathologically confirmed glial tumors. Immunohistochemistry for CD163 and CD8 was performed on formalin-fixed paraffin-embedded tissue sections. CD163 was scored as absent, weak, moderate, or strong, and CD8 infiltration was categorized as low or high. Associations with World Health Organization (WHO) tumor grade and histologic aggressiveness were analyzed using the chi-square test, Fisher's exact test, and Spearman's correlation. Results The mean age of the cohort was 42.7 ± 16.1 years, with males accounting for 29/50 (58.0%) and females for 21/50 (42.0%). High-grade gliomas comprised 32/50 (64.0%) cases, while low-grade tumors accounted for 18/50 (36.0%); grade IV tumors were the largest subgroup (20/50, 40.0%). CD163 positivity was observed in 40/50 (80.0%) tumors and increased significantly with tumor grade (rho = +0.59, p < 0.001). CD163 positivity was more frequent in high-grade than in low-grade tumors (30/32 (93.8%) vs. 10/18 (55.6%), p = 0.004). High CD8 infiltration was seen in 15/50 (30.0%) tumors and low CD8 infiltration in 35/50 (70.0%), with CD8 levels declining significantly with increasing grade (rho = -0.33, p = 0.021). Strong CD163 expression with low CD8 infiltration was present in 17/50 (34.0%) tumors and was significantly associated with high-grade lesions (16/32 (50.0%) vs. 1/18 (5.6%), p = 0.004). Moderate-to-strong CD163 expression was associated with necrosis (18/20 (90.0%), p = 0.009) and microvascular proliferation (16/18 (88.9%), p = 0.024). Conclusions Higher-grade glial tumors demonstrate a macrophage-dominant and CD8-restricted immune microenvironment. Combined assessment of CD163 and CD8 may serve as a practical indicator of aggressive tumor biology in routine diagnostic practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.